Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons..
Immunocompromised patients may experience prolonged viral shedding after their initial SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. We herein describe a severe COVID-19 relapse case of a kidney transplant recipient (KTR) following rituximab therapy, 3 months after a moderate COVID-19 infection, despite viral clearance after recovery of the first episode. During the clinical relapse, the diagnosis was established on a broncho-alveolar lavage specimen (BAL) by RT-PCR. The infectivity of the BAL sample was confirmed on a cell culture assay. Whole genome sequencing confirmed the presence of an identical stain (Clade 20A). However, it had an acquired G142D mutation and a larger deletion of 3-amino-acids at position 143-145. These mutations located within the N-terminal domain are suggested to play a role in viral entry. The diagnosis of a COVID-19 relapse should be considered in the setting of unexplained persistent fever and/or respiratory symptoms in KTRs (especially for those after rituximab therapy), even in patients with previous negative naso-pharyngeal SARS-CoV-2 PCR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 22(2022), 8 vom: 12. Aug., Seite 2099-2103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morel, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.08.2022 Date Revised 09.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.17000 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336823274 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336823274 | ||
| 003 | DE-627 | ||
| 005 | 20231225233021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.17000 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336823274 | ||
| 035 | |a (NLM)35150193 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morel, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2022 | ||
| 500 | |a Date Revised 09.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a Immunocompromised patients may experience prolonged viral shedding after their initial SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. We herein describe a severe COVID-19 relapse case of a kidney transplant recipient (KTR) following rituximab therapy, 3 months after a moderate COVID-19 infection, despite viral clearance after recovery of the first episode. During the clinical relapse, the diagnosis was established on a broncho-alveolar lavage specimen (BAL) by RT-PCR. The infectivity of the BAL sample was confirmed on a cell culture assay. Whole genome sequencing confirmed the presence of an identical stain (Clade 20A). However, it had an acquired G142D mutation and a larger deletion of 3-amino-acids at position 143-145. These mutations located within the N-terminal domain are suggested to play a role in viral entry. The diagnosis of a COVID-19 relapse should be considered in the setting of unexplained persistent fever and/or respiratory symptoms in KTRs (especially for those after rituximab therapy), even in patients with previous negative naso-pharyngeal SARS-CoV-2 PCR | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a clinical research/practice | |
| 650 | 4 | |a infection and infectious agents-viral | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a kidney transplantation/nephrology | |
| 650 | 4 | |a lung disease: infectious | |
| 650 | 4 | |a translational research/science | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Imbeaud, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Scemla, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Péré, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Fourgeaud, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Amrouche, Lucile |e verfasserin |4 aut | |
| 700 | 1 | |a Robillard, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Planas, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Puech, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Lanternier, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Bélec, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Zuber, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Anglicheau, Dany |e verfasserin |4 aut | |
| 700 | 1 | |a Chavarot, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Veyer, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 22(2022), 8 vom: 12. Aug., Seite 2099-2103 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:8 |g day:12 |g month:08 |g pages:2099-2103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.17000 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 8 |b 12 |c 08 |h 2099-2103 | ||